Big data reveals the characteristics of pancreatic tumors in Chinese
China News Service, September 12 (Reporter Chen Jing) The incidence of pancreatic cancer, known as the "king of cancer" in China, is increasing year by year, with high postoperative recurrence and high mortality; but the early diagnosis rate is low and surgical resection Low rate and low drug effectiveness.
At the 10th Pancreatic Cancer Shanghai Forum and the 5th China Pancreatic Tumor Conference held on the 12th, the China Pancreatic Disease Big Data Center (CPDC) released the latest four-year research data: Among Chinese patients undergoing pancreatic cancer surgery, there is pancreas Patients with a family history of cancer accounted for only 0.8% of the total; pancreatic cancer has a "male preference" situation, with a male to female ratio of 6:4; 61.7% of pancreatic cancers are pancreatic head cancers.
The conference on the same day was held online and offline, and authoritative medical experts from the field of pancreatic diseases had in-depth exchanges and discussions on topics such as "Pancreatic Cancer Precision Treatment System Construction", "Chinese Pancreatic Surgery Database Entry and Data Mining".
It is understood that since its establishment in 2017, the China Pancreatic Disease Big Data Center has gathered data on numerous pancreatic tumor patients from 88 top-tier hospitals in 31 provinces.
148 subject leaders participated in the joint construction, and more than 4.8 million structured statistical data information fields were collected through data governance.
Professor Yang Yinmo, Chairman of the Academic Committee of the Conference and Director of General Surgery of Peking University First Hospital, said frankly: "Although China does not lack clinical cases of pancreatic cancer, it lacks Chinese big data and evidence-based medical evidence to standardize and optimize pancreatic cancer for Chinese. "Guidelines for diagnosis and treatment." Yang Yinmo told reporters that past clinical experience believes that pancreatic cancer is highly affected by family genetic factors, but real-world data from CPDC show that genetic factors have little effect on the incidence of pancreatic cancer.
Sha Ou, the founder of a data technology company responsible for the development and construction of China's pancreatic disease big data center, told reporters that the CPDC construction model has borrowed from the National Cancer Institute related database co-construction and sharing mechanism and research service model, and innovated according to actual needs.
CPDC covers diagnosis, treatment, and follow-up diagnosis and treatment information.
AI data processing technology makes information processing and updating faster, more true and accurate.
CPDC data show that the population of pancreatic cancer is mainly middle-aged and elderly, and patients in the 60-75 age group account for 53.3% of the total.
Professor Wang Liwei, executive chairman of the conference, director of the Pancreatic Cancer Center of Shanghai Jiaotong University, and director of the Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, said: "CPDC's multi-center, multi-disciplinary high-quality data not only facilitates doctors to understand the pancreas more scientifically. Cancer can also guide the clinical diagnosis and treatment of pancreatic cancer."
Professor Lou Wenhui, deputy head of the Pancreatic Surgery Group of the Chinese Medical Association Surgery Branch and director of the Pancreatic Surgery Department of Zhongshan Hospital Affiliated to Fudan University, said in an interview that the pancreas is located at the back of the stomach, and there are no specific clinical manifestations in early pancreatic cancer. Patients will be mistaken for stomach diseases at first, and the early diagnosis rate is low.
In surgical treatment, open surgery accounts for more than 80%.
Lou Wenhui said that big data analysis can help doctors find factors that affect the survival and quality of life of patients, and try to avoid and reduce complications after surgery.
In the treatment of pancreatic cancer, surgery is only one aspect, and adjuvant treatment before and after surgery is essential.
Big data shows that the completion rate of postoperative adjuvant treatment for pancreatic cancer in China is less than 50%, and the adjuvant treatment before surgery is in the single digits.
In an interview, Wang Liwei said that at present, drug therapy is becoming more and more important in the comprehensive treatment of pancreatic cancer.
20% of locally advanced patients can also get the opportunity to operate after drug intervention.
As the chairman of the Chinese Society of Clinical Oncology (CSCO) Pancreatic Cancer Expert Committee and the head of the Pancreatic Oncology Group of the Oncology Branch of the Chinese Medical Association, Wang Liwei revealed that the China Pancreatic Disease Big Data Center (CPDC) is collecting data and information on the medical treatment of pancreatic cancer patients , Has included the relevant data of the first batch of 36 medical institutions. In the future, it will outline the full and true status of pancreatic tumors in China in a panoramic view, and provide a consistent basis for improving clinical diagnosis and treatment strategies and improving treatment guidelines.
(Finish)